|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
Valuation Estimation |
EPS (Current/Estimated)
-1.42/--
|
Enterprise Value
--
|
Balance Sheet |
Book Value Per Share
N/A
|
Cash Flow |
Cash Flow Yield
--
|
Income Statement |
Total Revenue
--
|
Operating Revenue Per Share
--
|
Industry Comparison
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
![](../images/dot.bmp)
Industry overview quotes are at least 15 minutes delayed
Business Description
|
|||
Sionna Therapeutics Inc is a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein to deliver clinically meaningful benefit to CF patients. CF is a progressive and life-threatening genetic disease caused by inherited mutations in the CFTR gene, which lead to insufficient CFTR function. |